Electrofisiología Cardíaca Celular

Tamargo, J; Delpón, E.

Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can't we see the evidence?

European Heart Journal-Cardiovascular Pharmacotherapy. 2025; : [doi:10.1093/ehjcvp/pvaf057]

Sandner, S; Gaudino, M; Agewall, S; Bonalumi, G; Bonaros, N; Czerny, M; Jeppsson, A; Milojevic, M; Niessner, A; Parolari, A; Sulzgruber, P; Tamargo, J; Thielmann, M; Wassmann, S; Zientara, A; Dobrev, D.

Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS)

EUROPEAN HEART JOURNAL. 2025; : [doi:10.1093/eurheartj/ehaf423]

Sandner, S; Gaudino, M; Agewall, S; Bonalumi, G; Bonaros, N; Czerny, M; Jeppsson, A; Milojevic, M; Niessner, A; Parolari, A; Sulzgruber, P; Tamargo, J; Thielmann, M; Wassmann, S; Zientara, A; Dobrev, D.

Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS)

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY. 2025; 67(8): [doi:10.1093/ejcts/ezaf243]

Camara-Checa, A; Alvarez, M; Rapún, J; Pérez-Martín, S; Núñez-Fernández, R; Rubio-Alarcón, M; Crespo-García, T; Desviat, LR; Delpón, E; Caballero, R; Richard, E.

Propionic Acidemia-Induced Proarrhythmic Electrophysiological Alterations in Human iPSC-Derived Cardiomyocytes

JOURNAL OF INHERITED METABOLIC DISEASE. 2025; 48(3): [doi:10.1002/jimd.70030]

Tamargo, J; Agewall, S; Ambrosio, G; Borghi, C; Cerbai, E; Dan, GA; Drexel, H; Ferdinandy, P; Grove, EL; Klingenberg, R; Morais, J; Parker, W; Rocca, B; Sulzgruber, P; Semb, AG; Sossalla, S; Kaski, JC; Dobrev, D.

New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024

European Heart Journal-Cardiovascular Pharmacotherapy. 2025; 11(3): 292-317 Nº de citas: 1 [doi:10.1093/ehjcvp/pvaf012]

Gigante, B; Tamargo, J; Agewall, S; Atar, D; ten Berg, J; Campo, G; Cerbai, E; Christersson, C; Dobrev, D; Ferdinandy, P; Geisler, T; Gorog, DA; Grove, EL; Kaski, JC; Rubboli, A; Wassmann, S; Wallen, H; Rocca, B.

Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis

European Heart Journal-Cardiovascular Pharmacotherapy. 2024; 10(7): 614-645 Nº de citas: 6 [doi:10.1093/ehjcvp/pvae064]

Casado-Arroyo, R; Bernardi, M; Sabouret, P; Franculli, G; Tamargo, J; Spadafora, L; Lellouche, N; Biondi-Zoccai, G; Toth, PP; Banach, M.

Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations

EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2024; 33(9): 967-978 Nº de citas: 1 [doi:10.1080/13543784.2024.2388583]

Fraile, A; Cebrián, J; Thuissard-Vasallo, I; Pérez-Martín, S; Casado, R; Gil-Fournier, B; Alonso-Martín, J; Tamargo, J; Caballero, R; Delpón, E; Cosío, FG.

Coexistent HCN4 and GATA5 Rare Variants and Atrial Fibrillation in a Large Spanish Family

CANADIAN JOURNAL OF CARDIOLOGY. 2024; 40(7): 1270-1280 Nº de citas: 1 [doi:10.1016/j.cjca.2024.02.024]

Gallego-Delgado, M; Cámara-Checa, A; Rubio-Alarcón, M; Heredero-Jung, D; de la Fuente-blanco, L; Rapún, J; Plata-Izquierdo, B; Pérez-Martín, S; Cebrián, J; de Redrojo, LM; García-Berrocal, B; Delpón, E; Sánchez, PL; Villacorta, E; Caballero, R.

Variable Penetrance and Expressivity of a Rare Pore Loss-of-Function Mutation (p.L889V) of Nav1.5 Channels in Three Spanish Families

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(9): Nº de citas: 1 [doi:10.3390/ijms25094686]

Tamargo, J; Agewall, S; Borghi, C; Ceconi, C; Cerbai, E; Dan, GA; Ferdinandy, P; Grove, EL; Rocca, B; Magavern, E; Sulzgruber, P; Semb, AG; Sossalla, S; Niessner, A; Kaski, JC; Dobrev, D.

New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023

European Heart Journal-Cardiovascular Pharmacotherapy. 2024; 10(3): 219-244 Nº de citas: 7 [doi:10.1093/ehjcvp/pvae013]

Tamargo, J; Villacastín, J; Caballero, R; Delpón, E.

Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect

PHARMACOLOGICAL RESEARCH. 2024; 200: Nº de citas: 5 [doi:10.1016/j.phrs.2024.107077]

Cámara-Checa, A; Perin, F; Rubio-Alarcón, M; Dago, M; Crespo-García, T; Rapún, J; Marín, M; Cebrián, J; Gómez, R; Bermúdez-Jiménez, F; Monserrat, L; Tamargo, J; Caballero, R; Jiménez-Jáimez, J; Delpón, E.

A gain- of- function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2023; 120(49): Nº de citas: 5 [doi:10.1073/pnas.2305135120]

Drexel, H; Tamargo, J; Kaski, JC; Lewis, BS; Saely, CH; Fraunberger, P; Dobrev, D; Komiyama, M; Plattner, T; Agewall, S; Hasegawa, K.

Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?

European Heart Journal-Cardiovascular Pharmacotherapy. 2023; 9(6): 570-582 Nº de citas: 21 [doi:10.1093/ehjcvp/pvad044]

Tamargo, J; Agewall, S; Borghi, C; Ceconi, C; Cerbai, E; Dan, GA; Ferdinandy, P; Grove, EL; Rocca, B; Sulzgruber, P; Semb, AG; Sossalla, S; Niessner, A; Kaski, JC; Dobrev, D.

New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

European Heart Journal-Cardiovascular Pharmacotherapy. 2023; 9(4): 353-370 Nº de citas: 24 [doi:10.1093/ehjcvp/pvad034]

Tamargo, J; Caballero, R; Mosquera, ED.

Sex and gender differences in the treatment of arterial hypertension

Expert Review of Clinical Pharmacology. 2023; 16(4): 329-347 Nº de citas: 8 [doi:10.1080/17512433.2023.2189585]

Crespo-García T; Rubio-Alarcón M; Cámara-Checa A; Dago M; Rapún J; Nieto-Marín P; Marín M; Cebrián J; Tamargo J; Delpón E; Caballero R.

A Cantú syndrome mutation produces dual effects on KATP channels by disrupting ankyrin B regulation.

JOURNAL OF GENERAL PHYSIOLOGY. 2023; 155(1): Nº de citas: 3 [doi:10.1085/jgp.202112995]

Dago, M; Crespo-Garcia, T; Camara-Checa, A; Rapun, J; Rubio-Alarcon, M; Marin, M; Tamargo, J; Caballero, R; Delpon, E.

Empagliflozin and Dapagliflozin Increase Na+ and Inward Rectifier K+ Current Densities in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells (hiPSC-CMs)

Cells. 2022; 11(23): Nº de citas: 8 [doi:10.3390/cells11233707]

Tamargo, J; Tamargo, M; Caballero, R.

Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline

EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2022; 31(10): 1027-1052 Nº de citas: 3 [doi:10.1080/13543784.2022.2113374]